Pharma Focus Asia
KP - Choose our fully recyclable blister films

ABVC BioPharma Receives Taiwan Science Park Administration's Approval for GMP Production Facility Plan

Friday, August 04, 2023

ABVC BioPharma has received approval from the Science Park Administration in Taiwan to establish a pilot Good Manufacturing Practise (GMP) facility. This facility will be dedicated to producing Vitargus®, an innovative product used in retinal detachment surgery.

In addition to production, ABVC BioPharma will focus on refining their manufacturing processes for optimal efficiency. The joint effort between ABVC's Taiwan affiliate and co-development partner, BioFirst Corporation focuses on the enhancement of manufacturing processes for Vitargus®. 

Vitargus®, a cutting-edge Vitreous Substitute, represents the first biodegradable hydrogel product intended for use in retinal detachment surgery. Having successfully concluded a feasibility study in Australia, Vitargus® received approval from the Australian Therapeutic Goods Administration (TGA) to proceed with the next phase of trials.

The focus on enhancing the facility's infrastructure is to yield substantial reductions in ongoing trial expenses, optimise production processes, kerbing costs linked to outsourcing to external Contract Research Organisations (CROs), and ensuring heightened operational efficiency.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024